Pharma Focus Europe

Kindeva Drug Delivery expands its facilities in Loughborough, UK, situated at the Charnwood Campus, to bolster the growth of green propellant commercialization

Wednesday, June 05, 2024

Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) specializing in drug-device combination products, has announced the expansion of its facilities in Loughborough, U.K., located within the Charnwood Campus Science Innovation and Technology Park. This expansion aligns with Kindeva's commitment to advancing green propellant commercialization and creating dedicated space for its commercial analytical laboratory services team, scheduled to move into the renovated area later this year.

The expansion will effectively double Kindeva's laboratory footprint in the U.K., supporting operational growth and the relocation of approximately 50 quality control employees from the Loughborough manufacturing site. Recently, the company also invested in a second manufacturing line at this facility to produce pressurized metered-dose inhaler (pMDI) products containing low Global Warming Potential (GWP) propellants. The expanded space offers potential for further growth and supports ongoing innovation and sustainability initiatives by consolidating development and ancillary capabilities in one location.

Carl Brookes, Vice President of Manufacturing and Operations – Loughborough at Kindeva, emphasized the significance of this expansion in advancing the commercialization of low GWP pMDI products. He reiterated Kindeva's commitment to leading in sustainable product transitions and highlighted the ongoing evaluation of sustainable technologies across all drug-device platforms and sites. Brookes also emphasized the importance of the Charnwood Campus expansion in maintaining operational excellence and ensuring the highest standards of product quality and safety, ultimately aiming to enhance patient health outcomes while contributing to environmental stewardship.



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024